.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Merck
Chubb
US Army
Cantor Fitzgerald
Moodys
Novartis
Federal Trade Commission
Fish and Richardson
Chinese Patent Office
Argus Health

Generated: June 28, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021360

« Back to Dashboard
NDA 021360 describes SUSTIVA, which is a drug marketed by Bristol Myers Squibb and is included in two NDAs. It is available from three suppliers. There are four patents protecting this drug and one Paragraph IV challenge. Additional details are available on the SUSTIVA profile page.

The generic ingredient in SUSTIVA is efavirenz. There are twenty-five drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the efavirenz profile page.

Summary for NDA: 021360

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Therapeutic Class:Antivirals
Formulation / Manufacturing:see details

Suppliers and Packaging for NDA: 021360

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
SUSTIVA
efavirenz
TABLET;ORAL 021360 NDA Bristol-Myers Squibb Pharma Company 0056-0510 0056-0510-30 30 TABLET, FILM COATED in 1 BOTTLE (0056-0510-30)
SUSTIVA
efavirenz
TABLET;ORAL 021360 NDA Physicians Total Care, Inc. 54868-4668 54868-4668-0 30 TABLET, FILM COATED in 1 BOTTLE (54868-4668-0)

Summary for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength300MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:Feb 1, 2002TE:RLD:Yes
Patent:6,639,071*PEDPatent Expiration:Aug 14, 2018Product Flag?Substance Flag?Delist Request?Y
Patent:6,939,964*PEDPatent Expiration:Jul 20, 2018Product Flag?Substance Flag?Delist Request?Y

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength600MG
Approval Date:Feb 1, 2002TE:ABRLD:Yes
Patent:6,639,071*PEDPatent Expiration:Aug 14, 2018Product Flag?Substance Flag?Delist Request?Y

Expired Orange Book Patents for NDA: 021360

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bristol Myers Squibb
SUSTIVA
efavirenz
TABLET;ORAL021360-001Feb 1, 20025,811,423► Subscribe
Bristol Myers Squibb
SUSTIVA
efavirenz
TABLET;ORAL021360-002Feb 1, 20025,811,423► Subscribe
Bristol Myers Squibb
SUSTIVA
efavirenz
TABLET;ORAL021360-001Feb 1, 20025,519,021*PED► Subscribe
Bristol Myers Squibb
SUSTIVA
efavirenz
TABLET;ORAL021360-001Feb 1, 20025,663,169*PED► Subscribe
Bristol Myers Squibb
SUSTIVA
efavirenz
TABLET;ORAL021360-002Feb 1, 20025,663,169*PED► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
US Department of Justice
Baxter
Harvard Business School
Daiichi Sankyo
Covington
Cerilliant
Teva
QuintilesIMS
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot